BioSpace News Archive

Stablix, Inc., a biopharmaceutical company pioneering targeted protein stabilization (TPS) as a novel therapeutic modality, today announced that Eddine Saiah, Ph.D., has joined the company as Chief Scientific Officer.

VBI Vaccines Inc. today announced that an abstract has been accepted for oral presentation at The International Liver Congress™ 2022 (ILC), the Annual Meeting of the European Association for the Study of the Liver (EASL), taking place June 22-26, 2022.

Veracyte, Inc. announced that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate in two upcoming investor conferences.

Devonian Health Group Inc. today announced the acceptance for publication of results from its positive phase 2 trial of Thykamine™ in patients with mild-to-moderate Atopic Dermatitis.

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) (SIX: ZBH), a global medical technology leader, today announced the appointment of Keri P. Mattox as Chief Communications and Administration Officer.

Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, announces that two abstracts featuring the Company’s RAS inhibitor program will be featured in the American Society for Clinical Oncology’s (ASCO) Annual Meeting Abstract Book.

VeriSIM Life (VeriSIM) www.verisimlife.com, the leading artificial intelligence (AI)-enabled, unique R&D decisions de-risker for breakthrough drug development, today announced that it has entered into a partnership agreement with Total Brain www.totalbrain.com.

According to Vision Research Reports, the Europe mobility aids market was valued at USD 2.9 billion in 2021 and it is predicted to surpass around USD 3.99 billion by 2030 with a CAGR of 3.61% from 2022 to 2030.

Multispecific Antibodies Cumulative Sales Have Already Surpassed USD 9 Billion By 2021 Says Kuick Research In Recent Reports On Bispecific & Trispecific Antibodies.

According to Vision Research Reports, the U.S. virtual care market was estimated at USD 4.3 billion in 2021 and it is expected to surpass around USD 46.5 billion by 2030, poised to grow at a CAGR of 30.28% from 2022 to 2030.